Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23527322 | 0.95 | ALDH1A1 (0.60) | ALDH1A1LMNAHPGDMAPTTSHR | |
| SCHEMBL23527298 | 0.94 | TSHR (0.57) | ALDH1A1LMNAHPGDMAPTTSHR | |
| SCHEMBL23527351 | 0.89 | ALDH1A1 (0.60) | ALDH1A1LMNAHPGDMAPTTSHR | |
| SCHEMBL23527370 | 0.89 | TSHR (0.53) | ALDH1A1LMNAHPGDMAPTTSHR | |
| SCHEMBL23527321 | 0.88 | MAPT (0.56) | ALDH1A1LMNAMAPTTSHRHDAC6 | |
| SCHEMBL23527186 | 0.88 | SMN1; SMN2 (0.65) | ALDH1A1LMNAHPGDMAPTTSHR | |
| SCHEMBL23527338 | 0.87 | PTGES (0.59) | ALDH1A1LMNAHPGDMAPTTSHR | |
| SCHEMBL23527319 | 0.86 | HPGD (0.57) | ALDH1A1LMNAHPGDMAPTTSHR | |
| SCHEMBL23527185 | 0.86 | SMN1; SMN2 (0.54) | ALDH1A1LMNAHPGDMAPTTSHR | |
| SCHEMBL21763932 | 0.86 | TDP1 (0.46) | ALDH1A1HPGDMAPTTSHRHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN LLC (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4075980-B1 | SUBSTITUTED 1,2, 4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163005-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12134605-B2 | Substituted 1,2,4-triazoles and methods of use | STINGINN, LLC (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240262796-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2024-08-08 | — | — | US | disclosed |
| US-20210188786-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188786-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2021-06-24 | — | — | US | disclosed |
| WO-2021127282-A1 | SUBSTITUTED 1,2, 4-TRIAZOLES AND METHODS OF USE | STINGINN LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188786-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STING1, IRF3, CGAS | ALDH1A1 3318/4885LMNA 4430/4885HPGD 1757/4885 |
| US-12134605-B2 | Substituted 1,2,4-triazoles and methods of use | STING1, IRF3, CGAS | ALDH1A1 3318/4885LMNA 4430/4885HPGD 1757/4885 |
| US-12600704-B2 | Substituted 1,2,4-triazoles and methods of use | STING1, IRF3, MAVS | ALDH1A1 3818/4885LMNA 1956/4885HPGD 3318/4885 |
| US-20250163005-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STING1, IRF3, CGAS | ALDH1A1 3318/4885LMNA 4430/4885HPGD 1757/4885 |
| US-20240262796-A1 | SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE | STING1, IRF3, CGAS | ALDH1A1 3318/4885LMNA 4430/4885HPGD 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.